Clinical trial · Observational
Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia
NCT04616274CI-TRIAL-00054723unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Venetoclax is a treatment for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). However, the pharmacokinetic data in Chinese population, as well as the change of venetoclax plasma concentration while taking CYP enzyme inducers or inhibitors, remained unknown so far. Therefore, the aim of this study is to investigate the pharmacokinetic characteristics of venetoclax.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Venetoclax | Drug | Venetoclax | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Venetoclax
- description
- Adult CLL patients (≥ 20 year-old) who have already initiated or are going to receive venetoclax treatment at National Taiwan University Hospital/National Taiwan University Cancer Center from July 2020 to December 2025.
- interventionNames
- Drug: Venetoclax
Primary outcomes (3)
- measure
- Area under curve (AUC) of venetoclax in Chinese population
- timeFrame
- July 1, 2020 to December 31, 2025
- description
- Area under curve (AUC) will be calculated through multiple plasma concentrations drawn from the patients after taking venetoclax.
- measure
- Half-life (T1/2) of venetoclax in Chinese population
- timeFrame
- July 1, 2020 to December 31, 2025
- description
- Half-life (T1/2) will be calculated through multiple plasma concentrations drawn from the patients after taking venetoclax.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients (≥ 20 year-old) with diagnosis of chronic lymphocytic leukemia * Patients who meet the above criteria and have already initiated or are going to receive venetoclax treatment at National Taiwan University Hospital/National Taiwan University Cancer Center from July 2020 to December 2025 Exclusion Criteria: * Patients who are unable to cooperate with blood drawing * Patients who have not submit the informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.